FAM86EP

Across TCGA pan-cancer cohorts, FAM86EP RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated FAM86EP data layer compared with 2 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FAM86EP RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM86EP expression acts as an unfavorable survival marker, although some lineages such as READ and BRCA show a favorable association.

LIHC, KICH, and LGG are the cancer types where FAM86EP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.465	0.614	<.001	54	view →
KICH	OS	Tertile	II,III,IV	0.480	1.000	.006	48	view →
LGG	DFS	Median	All	0.779	0.883	<.001	45	view →
LUAD	DFS	Tertile	All	0.260	0.478	.002	40	view →
DLBC	DFS	Median	II,III,IV	0.288	1.000	.002	19	view →
READ	DFS	Tertile	All	0.811	0.511	.003	19	view →
BRCA	OS	Tertile	III,IV	0.921	0.754	.002	17	view →
UVM	DFS	Quartile	III,IV	0.182	1.000	.006	12	view →
OV	OS	Quartile	All	0.897	0.768	.010	12	view →
ACC	DFS	Median	All	0.307	0.601	.019	10	view →
KIRP	DFS	Median	All	0.976	0.809	.015	6	view →
STAD	OS	Median	III,IV	0.544	0.723	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

FAM86EP–LIHC (DFS)

Open the LIHC breakdown →